Yes indeed. I've also heard that EU is the hardest market to crack into. From the conference, it appears that they need to do another clinical trial if they want to market to adolescence and children.
There doesn't appear to be a problem with the adult market. So likely for them to resubmit to cover a smaller market in EU. That's not too bad is it?
The $10m per year doesn't warrant a market cap of 175m though.
Ann: Ceasing to be a substantial holder , page-6
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
